Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4090601 | 0.94 | CTSS (0.57) | CTSSCD74 | |
| SCHEMBL4086108 | 0.93 | CTSS (0.59) | CTSSCD74 | |
| SCHEMBL4090657 | 0.93 | CTSS (0.58) | CTSS | |
| SCHEMBL4084869 | 0.92 | CTSS (0.70) | CTSSCD74 | |
| SCHEMBL4080410 | 0.92 | CTSS (0.57) | CTSSCD74 | |
| SCHEMBL4085377 | 0.92 | CTSS (0.72) | CTSSCD74 | |
| SCHEMBL4084388 | 0.91 | CTSS (0.57) | CTSSCD74 | |
| SCHEMBL4085879 | 0.91 | CTSS (0.59) | CTSSCD74 | |
| SCHEMBL4094459 | 0.91 | CTSS (0.58) | CTSSCD74 | |
| SCHEMBL4095167 | 0.91 | CTSS (0.57) | CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269241-A1 | BICYCLIC AMINOPROPYL TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | claimed |
| WO-2008100620-A2 | BICYCLIC AMINOPROPYL TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | claimed |
| US-20090118274-A1 | MONOCYCLIC AMINOPROPYL TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| US-20090118274-A1 | MONOCYCLIC AMINOPROPYL TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| US-20090118274-A1 | MONOCYCLIC AMINOPROPYL TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| US-20080269241-A1 | BICYCLIC AMINOPROPYL TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080269241-A1 | BICYCLIC AMINOPROPYL TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080269241-A1 | BICYCLIC AMINOPROPYL TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
| WO-2008100620-A2 | BICYCLIC AMINOPROPYL TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008100635-A1 | 1- [3- (MONOCYCLIC AMINO) PROPYL] - 4, 5, 6, 7-TETRAHYDRO-1H-PYRAZOLO [4, 3-C] -PYRIDINES AS MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269241-A1 | BICYCLIC AMINOPROPYL TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | CTSS, CTSK, CTSZ | CTSS 1/4885CD74 844/4885 |
| US-20090118274-A1 | MONOCYCLIC AMINOPROPYL TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | CTSS, CTSK, CTSZ | CTSS 1/4885CD74 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.